How should zonisamide be initiated, titrated, monitored, and what are its contraindications for an adult patient with focal seizures not controlled on a single antiepileptic drug?

Zonisamide for Refractory Focal Seizures in Adults

Initiation and Titration

Start zonisamide at 100 mg once daily, then increase to 200 mg/day after 2 weeks, with subsequent increases to 300 mg/day and 400 mg/day at 2-week intervals to allow steady-state levels to be achieved at each dose. 1

Starting Dose

• Begin at 100 mg daily (not 25 mg or 50 mg, despite availability of these strengths) 1
• Can be administered once or twice daily, with or without food 1
• Capsules must be swallowed whole 1

Titration Schedule

• Week 0-2: 100 mg/day 1
• Week 2-4: 200 mg/day 1
• Week 4-6: 300 mg/day 1
• Week 6+: 400 mg/day if needed 1

Rationale for Slow Titration

• Zonisamide has a long half-life requiring up to 2 weeks to reach steady state at each dose level 1
• Slower titration significantly improves tolerability and reduces treatment-emergent adverse events 2, 3
• The principle of "start low and go slow" applies to all newer antiepileptic drugs to minimize side effects 2

Effective Dose Range

The target maintenance dose is 300-400 mg/day, as doses above 400 mg/day show minimal additional benefit while increasing adverse effects. 2, 1

Evidence-Based Dosing

• 100-200 mg/day: 25% responder rate (50% seizure reduction) 2
• 300-400 mg/day: 43% responder rate 2
• Doses >400 mg/day: No clear evidence of increasing response 1
• Maximum studied dose is 600 mg/day, with little clinical experience beyond this 1

Real-World Practice

• Median maintenance dose in observational studies is 300 mg/day 4
• Responder rates of 55-66% achieved with 300-400 mg/day in clinical practice 4, 5

Monitoring Requirements

Clinical Monitoring

• Seizure frequency: Document at every visit to assess efficacy 4
• Adverse effects: Specifically assess for CNS effects (somnolence, dizziness, ataxia), weight loss, and psychiatric symptoms 2, 3
• Fluid intake: Ensure adequate hydration to prevent kidney stones 3

Laboratory Monitoring

• Baseline: Renal function, liver enzymes 1
• During treatment: Periodic monitoring of liver enzymes (transient elevations occur in 27.8% of patients) 5
• Serum levels: Not routinely necessary, as responders and non-responders show no difference in drug concentrations 2

Special Populations

• Renal or hepatic impairment: Requires slower titration and more frequent monitoring due to hepatic metabolism and renal excretion 1

Contraindications and Precautions

Absolute Contraindications

• Sulfonamide allergy: Patients with previous allergic reactions to sulfonamide-containing drugs are at higher risk for skin rash 3

Relative Contraindications and High-Risk Situations

• Psychiatric history: Psychiatric disturbances (irritability, confusion, depression) occur in >10% of patients and are more common in predisposed individuals 3, 6
• History of kidney stones: Renal calculi develop in 1.2% of patients on long-term therapy 6
• Concomitant topiramate or ketogenic diet: Increases kidney stone risk 3

Common Adverse Effects

Dose-Dependent CNS Effects

• Somnolence: Most frequent adverse effect (RR 1.52 vs placebo) 7
• Ataxia: RR 3.85 vs placebo 7
• Dizziness and fatigue: Among the five most common adverse events 2

Metabolic Effects

• Weight loss: Occurs in up to 10% of patients 6
• Anorexia: RR 2.74 vs placebo 7

Psychiatric Effects

• Agitation: RR 2.35 vs placebo 7
• Abnormal thinking, confusion, depression: Reported in clinical trials 2, 6

Idiosyncratic Reactions

• Oligohydrosis: Prevent by ensuring hydration and avoiding hot temperatures 3
• Skin rash: More common in patients with sulfonamide allergy history 3

Discontinuation Rates and Tolerability

• Discontinuation rate: 10-12% at therapeutic doses (100-400 mg/day), comparable to placebo 2
• High-dose intolerance: Discontinuation rates increase to 36% at 1200 mg/day and 67% at 2400 mg/day (doses not recommended) 2
• Overall, zonisamide is generally well-tolerated when titrated appropriately 4, 7

Clinical Pitfalls to Avoid

• Rapid titration: Increases treatment-emergent adverse events; always allow 2 weeks at each dose level 1, 3
• Inadequate hydration: Increases kidney stone risk; counsel patients to maintain fluid intake 3
• Combining with topiramate: Significantly increases kidney stone risk 3
• Ignoring psychiatric symptoms: Screen for and address mood/behavioral changes, especially in predisposed patients 3, 6
• Pushing doses >400 mg/day: Minimal additional efficacy with substantially increased adverse effects 2, 1